StockData
Amgen Inc logo

Amgen Inc (AMGN) stock

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 17/3026% above fair value
$457.93−4.39 (-0.95%)

Close on Nov 17, 2026Market cap $247.57BP/E 26.5Yield 2.11%

Amgen price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Amgen's price to book ratio was 21.7× on Nov 11, 2026, against 19.3× a year earlier. Over the last 5 years it ranged from 15.5× to 149.7×, with a median of 22.6×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202621.7×+3.3
2025Dec 31, 202518.3×−0.3
2024Dec 31, 202418.6×−1.5
2023Dec 29, 202320.1×−18.2
2022Dec 30, 202238.4×+22.9
2021Dec 31, 202115.5×+3.2
2020Dec 31, 202012.2×−1.2
2019Dec 31, 201913.4×+4.6
2018Dec 31, 20188.8×+4.9
2017Dec 29, 20173.9×+0.4
2016Dec 30, 20163.5×−0.8
2015Dec 31, 20154.4×−0.4
2014Dec 31, 20144.8×+0.8
2013Dec 31, 20134.0×+0.6
2012Dec 31, 20123.3×+0.9
2011Dec 30, 20112.4×+0.2
2010Dec 31, 20102.2×−0.3
2009Dec 31, 20092.5×–

More Amgen figures

See a number that looks wrong?